We are live on ! Find out more
BLACR

Bellevue Life Sciences Acquisition Corp. Rights
BLACR

Delisted

BLACR was delisted on the 14th of February, 2025.

Back to rankings

24 hedge funds and large institutions have $1.2M invested in Bellevue Life Sciences Acquisition Corp. Rights in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

37% more capital invested

Capital invested by funds: $879K → $1.2M (+$325K)

9% more funds holding

Funds holding: 22 → 24 (+2)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
24
Holders Change
+2
Holders Change %
+9.09%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
+$116K
2
CH
CVI Holdings
Delaware
+$30.8K
3
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
+$19.7K
4
UBS Group
UBS Group
Switzerland
+$999
5
CS
Clear Street
New York
+$156

Top Sellers

Rank Fund Capital Flow
1
SFM
Spartan Fund Management
Canada
-$6.02K
2
Citadel Advisors
Citadel Advisors
Florida
-$5.06K
3
Bank of America
Bank of America
North Carolina
-$39
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
1
Periscope Capital
Ontario, Canada
$209K +$116K +588,600 +185%
HCM
2
Highbridge Capital Management
New York
$206K – – –
PAMP
3
Polar Asset Management Partners
Ontario, Canada
$82.8K – – –
ASM
4
ATW SPAC Management
New York
$71.5K – – –
BFM
5
Boothbay Fund Management
New York
$71.5K – – –
SCM
6
Shaolin Capital Management
Florida
$58K – – –
RCM
7
Rivernorth Capital Management
Florida
$57.5K – – –
SCM
8
Saba Capital Management
New York
$57.5K – – –
SFM
9
Spartan Fund Management
Canada
$56K -$6.02K -30,528 -13%
ETH
10
Exos TFP Holdings
New York
$46K – – –
CH
11
CVI Holdings
Delaware
$43.7K +$30.8K +156,176 New
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$42K – – –
CS
13
Clear Street
New York
$34K +$156 +789 +0.5%
SOA
14
Sea Otter Advisors
Florida
$28.1K – – –
AA
15
AQR Arbitrage
Connecticut
$28K – – –
CC
16
Centiva Capital
New York
$28K – – –
WAM
17
Wolverine Asset Management
Illinois
$28K – – –
COPPSERS
18
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$23K +$19.7K +100,000 New
MTCM
19
Mint Tower Capital Management
Netherlands
$17K – – –
GF
20
Gabelli Funds
New York
$6.22K – – –
BI
21
Bulldog Investors
New Jersey
$4.97K – – –
GCIA
22
Gabelli & Co Investment Advisers
New York
$4.78K – – –
UBS Group
23
UBS Group
Switzerland
$1.17K +$999 +5,067 New
Bank of America
24
Bank of America
North Carolina
$23 -$39 -200 -67%
Citadel Advisors
25
Citadel Advisors
Florida
– -$5.06K -21,981 Closed

BLACR Hedge Fund Activity: Q3 2023 in Review

24 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q3 2023, worth a combined $1.2M — up 37% from $879K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BLACR positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Periscope Capital, adding an estimated $116K. The largest seller was Spartan Fund Management, cutting an estimated $6.02K.

  • 24 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q3 2023, up from 22 in Q2 2023.
  • Funds reported $1.2M of Bellevue Life Sciences Acquisition Corp. Rights stock for Q3 2023, up 37% quarter-over-quarter.
  • 3 funds opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q3 2023 and 1 closed out, a net change of +2 holders.
  • The largest Bellevue Life Sciences Acquisition Corp. Rights buyer in Q3 2023 was Periscope Capital, an estimated $116K added.
  • The largest Bellevue Life Sciences Acquisition Corp. Rights seller in Q3 2023 was Spartan Fund Management, an estimated $6.02K sold.

Based on aggregated 13F filings for Q3 2023.